Risk Factors and Risk Grading Prediction of Perioperative Respiratory Adverse Events in Children
1 other identifier
observational
600
1 country
1
Brief Summary
to explore the risk factors of perioperative respiratory adverse events in children, and to establish a risk prediction model of perioperative respiratory adverse events in children
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 3, 2024
CompletedFirst Posted
Study publicly available on registry
April 9, 2024
CompletedStudy Start
First participant enrolled
December 31, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2024
CompletedApril 9, 2024
April 1, 2024
Same day
April 3, 2024
April 3, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The occurrence of perioperative respiratory adverse events
Collection of respiratory adverse events including laryngeal spasm, Bronchospasm, decreased oxygen saturation, and increased secretions
perioperative
Eligibility Criteria
Children aged 1 month to 12 years, Asa Class I or II, scheduled for surgery under general anesthesia
You may qualify if:
- (1)Children aged 1 month to 12 years, (2) ASA Class I or II, (3)scheduled for surgery under general anesthesia
You may not qualify if:
- (1)Children and guardians declined to participate in the study (2) children with severe chronic respiratory, cardiovascular, central nervous system, liver and kidney diseases; (3) on the day of operation, the patients had active URTI and pulmonary infection, such as severe nasal obstruction, large amount of airway secretion, severe cough, fever (body temperature \> 37.5 ° C) , in addition to the above symptoms, signs of pulmonary consolidation and/or wet Rales, or peripheral white blood cells \> 10 × 109/L or \< 4 × 109/L with or without left shift of the nucleus, and chest X-ray showed new patchy, patchy infiltrative shadows or interstitial changes.
- (4) the child had severe anaphylaxis to narcotic drugs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sichuan provincial Peopel'Hospital
Chengdu, Sichuan, China
Study Officials
- STUDY DIRECTOR
Ting Xu
Sichuan provincial Peopel'Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
April 3, 2024
First Posted
April 9, 2024
Study Start
December 31, 2024
Primary Completion
December 31, 2024
Study Completion
December 31, 2024
Last Updated
April 9, 2024
Record last verified: 2024-04